Sling Therapeutics, a clinical-stage biopharmaceutical company developing the first and only late-stage oral small-molecule therapy for thyroid eye disease (TED), announced the close of a $123 million Series C financing. The financing was led by Forbion and included participation from existing investor TPG Life Sciences Innovations and new investor Sectoral Asset Management.